Paper Details

  1. Home
  2. Paper Details

Voxelotor for the treatment of sickle cell disease in pediatric patients.

Author: AbboudMiguel R, BrownClark, TondaMargaret

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This review provides an overview of sickle cell disease (SCD) and the role of voxelotor, a novel oral therapy, in managing the disease. Voxelotor inhibits the polymerization of sickle hemoglobin, reducing the incidence of end-organ damage (EOD).
Paper Details　
Original Abstract of the Article :
Sickle cell disease (SCD) describes a group of heritable blood disorders caused by the polymerization of sickle hemoglobin (HbS). HbS polymerization leads to anemia and vaso-occlusion, a process that impedes delivery of oxygen to tissues throughout the body, resulting in end-organ damage (EOD). Give...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1080/17474086.2022.2082408

データ提供：米国国立医学図書館（NLM）

Voxelotor: A New Hope for Sickle Cell Disease in Children

This research focuses on a new treatment, voxelotor, for sickle cell disease (SCD) in pediatric patients. The study explores the mechanism of action of voxelotor, a drug that inhibits the polymerization of sickle hemoglobin, and its potential to reduce the complications associated with SCD.

Voxelotor: A Breakthrough in Sickle Cell Disease Treatment

The research highlights the potential of voxelotor to alleviate the debilitating symptoms of SCD. By inhibiting the polymerization of sickle hemoglobin, voxelotor offers a unique approach to reducing the risk of vaso-occlusion and end-organ damage, key complications associated with SCD.

A Brighter Future for Children with Sickle Cell Disease

Imagine a world where children with SCD can live a life free from the limitations of their condition. This research presents a promising new treatment for SCD, offering hope for a better quality of life for children affected by this debilitating disease.

Dr. Camel's Conclusion

This research presents a significant advancement in the treatment of sickle cell disease. Voxelotor offers a new avenue for alleviating the symptoms of SCD and improving the lives of children affected by this condition. It represents a beacon of hope for a brighter future for these young patients.

Date :
  1. Date Completed 2022-06-22
  2. Date Revised 2022-10-15
Further Info :

Pubmed ID

35671094

DOI: Digital Object Identifier

10.1080/17474086.2022.2082408

Related Literature

Article Analysis
・Causes of blood disorders・Effects of voxelotor
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.